iTeos Therapeutics a biotechnology company developing novel cancer immunotherapies, announced Dr Mohamed Ragab has been appointed as Vice President of Corporate Development.
He will be responsible for overseeing global strategic business opportunities that support the growth of iTeos both clinically and operationally.
Dr Ragab was most recently the Vice President of Search and Evaluation Oncology at Bristol-Myers Squibb where he was involved in many major immune-oncology deals.
Dr Ragab, Vice President of Corporate Development at iTeos, said: "I am excited to be joining iTeos during this period of rapid growth, particularly as the company is growing their presence in the US.
"iTeos has the science and technology to be at the forefront of cancer immunotherapies and I look forward to working with the team to advance the pipeline as rapidly as possible."
Prior to that, he was Global Partnering Head of Oncology at Hoffman-La Roche (part of Roche Group) and before that he was the Life Cycle Leader at Anemia Oncology.
He also held various positions at Pfizer, Ortho Biotech and Schering-Plough. He holds a Master Degree in Radiation Oncology from Cairo University School of Medicine and holds a Bachelor of Medicine and Surgery from Cairo University School of Medicine.
Dr Michel Detheux, CEO at iTeos, said: "We are delighted Dr Ragab has joined iTeos and this is testament to the progress that we have made that we are now appointing someone of his caliber to our executive team.
"He has over 20 years of experience with strategic planning, business development and licensing deals specifically in oncology. His expertise will be invaluable as iTeos looks to expand its pipeline and explore the best strategic options for our proprietary drug programs."
